School of Medicine


Showing 1-17 of 17 Results

  • Rachel Hagey Saluti

    Rachel Hagey Saluti

    Staff Research Scientist, Medicine - Med/Gastroenterology and Hepatology

    BioMy primary research focus is in translational molecular virology and drug discovery/development. My work aims to uncover and characterize novel virus targets for the rational design of new classes of antiviral therapeutics.

  • Adrish Sen

    Adrish Sen

    Affiliate, Medicine - Med/Gastroenterology and Hepatology

    BioMy research focuses on Rotavirus (RV) - the causative agent of acute infantile diarrhea, that is responsible for more than 200,000 deaths annually. My earlier work explored RV molecular epidemiology and virion assembly mechanisms. This led to the identification of novel group B rotaviruses, which cause adult diarrhea in humans and exhibit pandemic potential. I subsequently characterized molecular mechanisms by which rotaviruses assemble in infected cells - specifically how a viral non-structural protein, NSP5, forms higher-order assembly scaffolds by a calcium-triggered reversible molecular switch.
    Since moving to Stanford University, my research in Dr. Harry Greenberg’s laboratory has focused on understanding the role that innate immunity plays in determining rotavirus species barriers, pathogenicity, and shaping the overall immune response to natural and vaccine-related RV infections. Our work defined the pathways leading to RV recognition by the host interferon response and uncovered viral strategies to regulate this process. Single-cell studies have revealed that RV degrades all three major IFN type receptors in infected cells, and remarkably, also confers pleiotropic IFN resistance to RV-bystander cells (which express normal levels of IFN receptors). These viral regulatory mechanisms possibly underlie the unexpected ability of RV infection to prevent lethal endotoxemia, which we reported recently. I have a strong interest in dissecting host antiviral responses to pathogenic and attenuated viruses at the population and single-cell levels using microfluidics qRT-PCR, multi-color cytometry, and novel mass cytometry techniques. In other ongoing research, I am examining differences in cell type-specific innate responses to pathogenic and attenuated influenza viruses in the human nasal mucosa (primarily using clinical and volunteer nasal swab specimens).

  • Atulkumar T. Shah, MD

    Atulkumar T. Shah, MD

    Clinical Instructor, Medicine - Gastroenterology & Hepatology

    BioDr. Shah is a board-certified, fellowship-trained gastroenterologist with Stanford Health Care’s Digestive Health program. He is a clinical associate professor of medicine in the division of Gastroenterology and Hepatology at Stanford University School of Medicine.

    Dr. Shah treats all gastrointestinal and liver conditions, such as gastroesophageal reflux disease (GERD), colon polyps, hepatitis, inflammatory bowel disease, and irritable bowel syndrome. He has a special interest in the increasingly prevalent fatty liver disease, which allows him to work closely with patients to educate them about symptom management and making lifestyle changes that will improve their health and wellbeing.

    Dr. Shah treats all gastrointestinal and liver conditions, such as gastroesophageal reflux disease (GERD), colon polyps, hepatitis, inflammatory bowel disease, and irritable bowel syndrome. He has a special interest in the increasingly prevalent fatty liver disease, which allows him to work closely with patients to educate them about symptom management and making lifestyle changes that will improve their health and wellbeing.

    After more than two decades of practice, Dr. Shah added training in liver transplant to expand his knowledge of liver disease and offer his patients a “one-stop” resource for truly comprehensive care.

    Dr. Shah is a member of the American College of Gastroenterology, American Society of Gastrointestinal Endoscopy, and American Association for the Study of Liver Disease.

    Among Dr. Shah’s current research interests is the development of an algorithm assessing the impact of gastrointestinal disease management on readmission rates.

    Dr. Shah brings a personalized approach to working with patients and to teaching the next generation of physician scientists the classic skills of careful listening and patient examination. Throughout his career, he has emphasized the fundamental importance of balancing scientific expertise with empathy and compassion.

    As a volunteer with the non-profit organization Health Volunteers Overseas, Dr. Shah travels around the world to train physicians about liver disease management and treatment. He is director of the HVO site in Bangalore, India.

  • Edward Sheen

    Edward Sheen

    Adjunct Professor, Medicine - Med/Gastroenterology and Hepatology

    BioEdward Sheen is Chief Medical Officer, Market Development and Solution Design at Lumeris. Lumeris is a leading value-based care delivery operator aligning and transforming health systems and payers across the country to improve population health, reduce costs of care, enhance patient experience, and strengthen care provider engagement. Through its operations, technology, change management, and strategic advisory solutions, Lumeris establishes population health services organizations and collaborative, aligned health plans to deliver accountable person-centered care.

    His experience has bridged the public, private, non-profit, and academic sectors and includes work with Stanford University, the White House, U.S. Department of Defense, U.S. Department of Health and Human Services, California State Assembly, Kaiser Family Foundation, Blue Shield of California, California/American Medical Associations, and Genzyme, as well as advising early stage healthcare companies. In 2014 he was one of 15 Americans appointed by President Barack Obama a nonpartisan White House Fellow, and selected to be the White House Fellow to the Secretary of Defense. In this capacity, he served as a Special Assistant to the Secretary and Defense Department senior health policy adviser, and was a recipient of the Office of the Secretary of Defense Medal for Exceptional Public Service. Dr. Sheen is also Adjunct Professor of Medicine, a Global Health Faculty Fellow, and Term Member of the Council on Foreign Relations. He is dedicated to achieving more accessible, innovative, patient-centered, and high-performing health care and bringing together teams and communities to care for vulnerable populations. Additionally, he has a long commitment to mentoring, medical education, and the leadership development of future change agents, and works with students throughout the year.

    Dr. Sheen completed his Internal Medicine and Gastroenterology training at Stanford, received his MD from the University of California, San Francisco and earned his MBA and MPH degrees through scholarships from Stanford Graduate School of Business and Harvard School of Public Health, where he was also a Harvard Kennedy School Center for Public Leadership Zuckerman Fellow. He graduated magna cum laude from Brown University with a B.A. in Public Policy and induction to Phi Beta Kappa.

  • Sundeep Singh

    Sundeep Singh

    Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

    BioAfter living and training throughout the country, I am excited to be part of the Stanford team. As a result of both my personal experiences and training, I am passionate about ensuring that patients receive appropriate diagnostic testing and treatment options in order to improve people's quality of life. In collaboration with my amazing colleagues, I am confident in the high quality and easily accessible care we are able to provide to patients across northern California.

    While my interest is most in inflammatory bowel disease, I am also interested in the interaction between mental health, incentives, and emerging therapies in gastroenterology.

  • Sidhartha Sinha

    Sidhartha Sinha

    Assistant Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University Medical Center

    Current Research and Scholarly InterestsThere are two primary and overlapping emphases of my research, both of which are driven and united by needs-based innovation and translational potential:

    (1) Understanding the microenvironment of the inflamed versus normal gut in order to identify better therapeutic targets for people with immune-¬mediated GI disorders. Here, our investigations include understanding the influence and interactions of pharmacologic and dietary interventions on gut microbiome/metabolomic changes and the host immune response. In the context of providing patients with new understanding and solutions for their disease, I have led and advised on the design of both pilot and large clinical trials (including new FDA approved therapies) for anti-inflammatory therapies;

    (2) Applying novel approaches and technologies (including natural language processing, computer vision, and reinforcement learning) to identify and address unmet clinical needs. In this area we have ongoing and published efforts in my lab to validate and develop solutions to pressing clinical needs. We have developed/led new drug delivery technologies with a multidisciplinary team that have shown strong potential in ongoing human IBD clinical trials. My lab has utilized both supervised and unsupervised approaches to analyze social media discourse and unstructured data sets for identifying patient needs that are rarely addressed in clinical settings. We have gained insights into patient perceptions around preventative health interventions, such as health screening and diet, including the dearth of evidence-based dietary recommendations to treat IBD (despite strong patient desire for solutions in this domain).

  • Irene Sonu

    Irene Sonu

    Clinical Assistant Professor, Medicine - Gastroenterology & Hepatology

    BioI am passionate about gut health and strive to provide the best care to my patients. I specialize in complex motility disorders of the gastrointestinal tract. My areas of clinical expertise include achalasia, dysphagia, eosinophilic esophagitis, gastroesophageal reflux disease, gastroparesis, functional dyspepsia, irritable bowel syndrome, and pelvic floor dysfunction. I also see patients in need of fecal microbiota transplant for recurrent C. difficile infection.

  • Sarah Streett

    Sarah Streett

    Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

    BioDr. Sarah Streett is the Clinical Director of Inflammatory Bowel Disease at Stanford and is passionate about taking care of people with IBD. She is a national expert in the treating of complex IBD and is expanding our services to offer multi-disciplinary care and opportunities for clinical research participation. In 2018 she received the Champion of Hope Award from the Crohn’s and Colitis Foundation and serves on their Medical Advisory Board. Her interests are in fertility and pregnancy in people with IBD, developing precision approaches to IBD therapy, and in the role that the microbiome and diet play its pathogenesis. She is one of the investigators in the Stanford IBD Registry and has research projects focused on optimizing clinical outcomes in IBD, the role of the microbiota and diet in IBD and pregnancy and applying new technologies to individualizing therapy for IBD.

    Dr. Streett has a national leadership role in the American Gastroenterological Association, where has been Chair of the Practice Management and Economics Committee, as well as Chair of the AGA’s initiatives on Obesity. She currently serves on the Government Affairs Committee and is a special government employee at the FDA. She has represented the interests of gastroenterologists and their patients on Capitol Hill numerous times. Dr. Streett believes strongly in a collaborative approach to give patient’s personalized care based on the latest therapies for the treatment of IBD.